Skye Bioscience Inc Dossier - Source-backed chat

Skye Bioscience Inc

SKYENASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)2.29

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $1.60Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $7.1M

Enterprise Value −$733.7K

Shares Outstanding 4.4M diluted

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Skye Bioscience is a clinical-stage biotechnology company focused on developing nimacimab, a peripherally-restricted CB1 inhibitor antibody, for obesity and metabolic disorders. Although nimacimab monotherapy failed to meet its primary weight loss endpoint in the Phase 2a CBeyond study, the combination of nimacimab and semaglutide demonstrated clinically meaningful, synergistic weight loss (13.2% at 26 weeks and 22.3% at 52 weeks) with an exceptionally clean safety profile, showing no neuropsychiatric or increased gastrointestinal adverse events. The current investment thesis centers on the potential of higher-dose nimacimab (currently being evaluated in the CBeyond Part C expansion study) to optimize drug exposure and unlock significant therapeutic value in combination with GLP-1 receptor agonists.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets5 analysts · as of 18 Aug 2026

Low · most bearish analyst$2.00

Mean target$7.60

High · most bullish analyst$20.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$2.0020%

Higher doses of nimacimab fail to significantly improve drug exposure or introduce unexpected safety/tolerability concerns, rendering the asset non-viable for further combination development. Skye faces severe capital constraints as its cash runway expires in late 2026, forcing a highly dilutive capital raise or restructuring, driving the stock down toward its cash value.

Base CaseCentral scenario

$7.3355%

The higher-dose expansion study provides sufficient exposure-response data by Q4 2026 to select an optimized dose for Phase 2b. The combination therapy continues to show strong durability and safety. Skye raises additional capital through equity dilution or a mid-sized licensing deal to fund the Phase 2b trial, with the stock moving toward the consensus analyst target.

Bull CaseUpside scenario

$20.0025%

The CBeyond Part C expansion study successfully demonstrates that higher doses of nimacimab achieve the predicted serum exposure levels without compromising its favorable safety profile. This enables a highly competitive Phase 2b combination trial, positioning nimacimab as a best-in-class peripheral CB1 inhibitor. Skye secures a lucrative strategic partnership with a major pharmaceutical company, fully funding the Phase 2b trial and driving the stock toward the high analyst target.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Clinically meaningful synergistic weight loss (22.3% at 52 weeks) when nimacimab is combined with semaglutide.
Differentiated safety profile with no neuropsychiatric side effects (a historical hurdle for CB1 inhibitors) and no increase in gastrointestinal adverse events.
Durability advantage, with the combination cohort showing over 50% reduction in weight regain during treatment interruption compared to semaglutide alone.
Active clinical catalyst with the CBeyond Expansion Study (Part C) evaluating higher doses, with topline data expected in Q4 2026.

Key Investment Risks

Limited cash runway extending only through Q4 2026, which excludes the substantial costs of the proposed Phase 2b trial and additional manufacturing.
Clinical development risk, as there is no guarantee that higher dosing of nimacimab will successfully translate into increased drug exposure or efficacy.
High reliance on a single clinical asset (nimacimab) following the failure of its monotherapy arm to meet the primary endpoint.

Thesis Invalidation Triggers

Failure of the CBeyond Expansion Study (Part C) to demonstrate improved drug exposure or dose-response at higher doses.
Emergence of any neuropsychiatric or severe gastrointestinal safety signals in ongoing higher-dose cohorts.
Inability to secure additional financing or a strategic partnership before the current cash runway expires in Q4 2026.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.